PPIAL4F: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Target Name: PPIAL4F

NCBI ID: G728945

PPIAL4F

PPIAL4F: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, and chronic obstructive pulmonary disease (COPD), cause significant morbidity and mortality worldwide. Chronic inflammation in these diseases can lead to structural damage, functional impairments, and a heightened risk of complications. The protein PPIAL4F (Pro-inflammatory response-related gene 4F) has been identified as a potential drug target and biomarker for the treatment of inflammatory diseases.

PPIAL4F: Structure and Function

PPIAL4F is a cytoplasmic protein that plays a crucial role in the regulation of inflammatory responses. It is a member of the PPIAL gene family, which is known to be involved in the regulation of pro-inflammatory cytokines, chemokines, and bacterial translocation. PPIAL4F is expressed in a variety of tissues and cells, including macrophages, dendritic cells, and epithelial cells, and its function is to regulate the production and response to pro-inflammatory mediators.

PPIAL4F is a 21-kDa protein that consists of an N-terminus, a catalytic domain, and a C-terminus. The N-terminus of PPIAL4F contains a putative transmembrane region that is involved in the formation of a complex with other proteins, such as the transcription factor NF-kappa-B. The catalytic domain of PPIAL4F contains a unique ATP-binding site and is involved in the regulation of cellular processes, including DNA replication, gene expression, and protein synthesis.

PPIAL4F is involved in the regulation of pro-inflammatory responses by suppressing the production and activity of pro-inflammatory cytokines and chemokines. Specifically, PPIAL4F has been shown to regulate the production of pro-inflammatory cytokines, such as TNF-伪, IL-1, and IL-6, by inhibiting the activation and translocation of the transcription factor NF-kappa-B. Additionally, PPIAL4F has been shown to regulate the production of chemokines, such as IL-2, by inhibiting the activation and translation of the transcription factor CSL2.

PPIAL4F is also involved in the regulation of bacterial translocation, which is a critical step in the pathogenesis of inflammatory diseases. PPIAL4F has been shown to translocate bacterial toxins into the cytoplasm and to regulate the production of pro-inflammatory cytokines by modulating the activity of the transcription factor NF-kappa-B.

Drug Targeting and Biomarker Potential

The potential drug targeting of PPIAL4F is based on its involvement in the regulation of pro-inflammatory responses. Drugs that target PPIAL4F and modulate its activity could potentially be effective in treating inflammatory diseases.

One approach to drug targeting PPIAL4F is to target its N-terminus, which contains a putative transmembrane region that is involved in the formation of a complex with other proteins. Drugs that specifically target this region could potentially disrupt the interaction between PPIAL4F and other proteins and disrupt its function in the regulation of pro-inflammatory responses.

Another approach to drug targeting PPIAL4F is to target its catalytic domain, which contains a unique ATP-binding site. Drugs that specifically target this site could potentially disrupt the activity of PPIAL4F and regulate its function in the regulation of cellular processes, including DNA replication, gene expression, and protein synthesis.

As a potential biomarker for the treatment of inflammatory diseases, PPIAL4F could be used to monitor the effectiveness of different treatments. For example, if a patient with rheumatoid arthritis is treated with a drug that targets PPIAL4F, the levels of PPIAL4F and its associated proteins, such as TNF-伪 and IL-6, can be monitored to assess the effectiveness of the treatment. Similarly, if a patient with inflammatory bowel disease is treated with a drug that targets PPIAL4F, the levels of PPIAL4F and its associated proteins can be monitored to assess the effectiveness of the treatment.

Conclusion

In conclusion, PPIAL4F is a potential drug target and biomarker for the treatment of inflammatory diseases. Its involvement in the regulation of pro-inflammatory responses makes it an attractive target for small molecule inhibitors. Further studies are needed to fully understand the function of PPIAL4F and to develop effective treatments for inflammatory diseases.

Protein Name: Peptidylprolyl Isomerase A Like 4F

Functions: PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides (By similarity)

The "PPIAL4F Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPIAL4F comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets